10 nov: Aktietilbagekøbsprogram
10 nov: Indre værdi af SmallCap Danmark A/S er opgjort til 82,7 kr. pr. ..
10-11-2017 07:30:00

Nine-month interim report (Q3) 2017

Relateret indhold
12 nov - 
Aktier/tendens: Pilen peger opad for børsdagen
09 nov - 
Fredagens aktier: Klø til Chr. Hansen sendte C25 på wee..
09 nov - 
Aktier/middag: Chr. Hansen trækker C25 i rødt efter sto..
Relateret debat
17 nov - 
Hvorfor falder kursen når Helleman har meldt ud at USA ..
15 nov - 
Jeg synes ikke den nuværende direktør lever op til forg..
12 nov - 
Ok, men din måde at formulere det på, lignede et citat ..

København, 2017-11-10 07:30 CET (GLOBE NEWSWIRE) --

 

Bemærk venligst, at kvartalsrapporten kun foreligger på engelsk.  

Performance for the period (unaudited)

(Comparative figures for 2016 are shown in brackets. Revenue growth is measured in local currencies. 2016 comparative figures are affected by last year's market disruptions which boosted ALK's sales and earnings in Europe significantly. To provide a meaningful benchmark, comparisons to figures from 2015 have also been included in the report wherever relevant.)

During Q3 2017, ALK continued its investment programme to scale-up and build a pharma company in North America, defend its European leadership position and upgrade its product supply. ALK will continue to invest to deliver its long-term growth plans.    

Q3 2017 highlights:

  • Sales growth in Europe, North America and International markets showed good progress in line with expectations.

  • Total revenue increased 7% to DKK 667 million (630), with European revenue 23% higher organically than 'pre-market disruption' levels in Q3 2015.

  • Constraints in SCIT production capacity are estimated to have negatively impacted Q3 sales by DKK 50-60 million.

  • Operating profit (EBITDA) was DKK 36 million (110) following planned cost increases to support long-term growth, including the launch of the HDM SLIT-tablet in North America and to secure robustness in ALK's product supply operations.

  • 9M total revenue amounted to DKK 2,147 million (2,251) and 9M operating profit (EBITDA) was DKK 192 million (546).

Business priorities

  • Investments in the North American scale-up to support the launch of SLIT-tablets are ongoing. In August, the marketing authorisations were transferred to ALK from the FDA. In November, ALK has launched the HDM SLIT-tablet as ACARIZAX® in Canada and has started pre-launch and marketing activities ahead of the launch in the USA, where the brand name will be ODACTRA™. Market access in the USA is progressing well.

Investments to defend and retain market leadership in Europe continue and showed good results in Q3.

  • ACARIZAX® sales in Europe roughly doubled in Q3, while development, registration and market access activities are progressing.

  • Investments in securing a robust product supply continue. Robust inventory levels are expected to be gradually rebuilt during 2018.

  • In December 2017, ALK will be presenting an updated strategy that is designed to stimulate a new era of growth by continuing ALK's investments in its core AIT franchise while also leveraging its position and expertise to engage with more patients and to capture a larger share of the total allergy market.

  • 2017 financial guidance

    ALK's financial guidance for full-year revenue has been narrowed while guidances for operating profit (EBITDA) and free cash flow remain unchanged:

    • Full-year revenue is now projected at approximately DKK 2.9 billion (previously DKK 2.8-3.0 billion) as European markets establish a 'new normal' following last year's disruptions. 

    • Operating profit (EBITDA) is still expected to be DKK 225-250 million.

    • Free cash flow is still expected at approximately minus DKK 700 million.

    Hørsholm, 10 November 2017

    ALK-Abelló A/S

     

    For further information, contact:

    Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

    Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014 

    Today, ALK is hosting a conference call for analysts and investors at 10.00 a.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net/. Participants for the audio cast are kindly requested to call in before 9.55 a.m. (CET). Danish participants should call in on tel. +45 7022 3500 and international participants should call in on tel. +44 (0) 20 7572 1187 or +1 646 722 4972. Please use the Participant Pin Code: 28359539#. The conference call will also be webcast live on our website, where the related presentation will be made available shortly before the call begins.  

    Vedhæftet fil: FM_30_17UK_10112017.pdf

    Opret kommentar

    Relateret debat

    • 1 uge
    • 1 måned
    • 1 År
    Ingen indlæg

    DFDS/Morgan Stanley: Kursmål sænkes til 335 kr. fra 380 kr. - NY

    20-11-2018 13:52:05
    Rederiet DFDS får sænket kursmålet til 335 kr. fra 380 kr. af Morgan Stanley, der dog fastholder den neutrale anbefaling "ligevægt".Det er blandt andet bekymringer om brexit og den tyrkiske eksponering, der får finanshuset til at sænke kursmålet, skriver Bloomberg News.DFDS-aktien falder tirsdag med 4,3 pct. til 237,40 kr. i et generelt negativt marked. /ritzau/FINANS

    Danske Bank: Whistleblower kan frit offentliggøre tavshedsklausul

    20-11-2018 11:14:35
    Danske Bank vil ikke stoppe briten Howard Wilkinson, der forsøgte at advare om hvidvask i bankens estiske filial, i at offentliggøre sin fratrædelsesaftale fra 2014, hvis han ønsker det.Det oplyser Danske Bank til Bloomberg News.- Vi vil ikke have noget imod, at Howard Wilkinson offentliggør hele eller dele af sin fratrædelsesaftale, lyder det i en mail fra banken, der dog ikke selv har planer om ..

    Aktier/tendens: Tryg og Top i fokus i ventet negativ åbning

    20-11-2018 08:06:01
    Sænkede anbefalinger bringer fokus på forsikringsaktierne Tryg og Topdanmark fra åbningen tirsdag, hvor meget tyder på fald fra start efter negative markeder i USA mandag aften og nedtur også på de asiatiske børser tirsdag. Store fald i Faang-aktierne, som Apple, Facebook og Amazon, rev mandag tæppet væk under det amerikanske aktiemarked, hvor S&P 500-indekset lukkede 1,7 pct. lavere og faldt hele..

    Mest læste nyheder

    • 24 timer
    • 48 timer
    • 1 uge
    1
    Aktier/middag: Novo og bryggerier mildest ramt af generel uro
    2
    Bitcoin fortsætter brat nedtur
    3
    Bankaktier er ramt af dårlig stemning og usikkerhed i Europa
    4
    Aktier/tendens: Tryg og Top i fokus i ventet negativ åbning
    5
    Aktier/åbning: Bred nedgang i C25 anført af WDH og GN

    Relaterede aktiekurser

    ALK-Abelló B A/S 951,00 -1,1% Fald i aktiekurs

    Køb- og salgssignaler

    • Trend
    • Pengemaskinen

    Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
    Aktieinformation leveres af Morningstar.
    Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
     
    20. november 2018 21:17:08
    (UTC+01:00) Brussels, Copenhagen, Madrid, Paris
    Version: LiveBranchBuild_20181114.1 - EUROWEB3 - 2018-11-20 21:17:08 - 2018-11-20 21:17:08 - 1 - Website: OKAY